Table 1. Baseline clinical characteristics of patients according to testing status.
| Characteristic | COVID-19 Not Tested | COVID-19 Tested | P | COVID-19- | COVID-19+ | P |
|---|---|---|---|---|---|---|
| Number | 25,803 | 900 | 694 | 206 | ||
| Age | 76 (65–85) | 73 (62–82) | <0.001 | 72 (61–81) | 78 (65–87) | <0.001 |
| Female | 11,701 (45.3%) | 457 (50.8%) | <0.001 | 344 (49.6%) | 113 (54.9%) | 0.18 |
| Black | 3,414 (13.2%) | 205 (22.8%) | <0.001 | 143 (20.6%) | 62 (30.1%) | <0.05 |
| White | 19,824 (76.8%) | 598 (66.4%) | <0.001 | 479 (69.0%) | 119 (57.8%) | <0.05 |
| Medicare | 11,032 (42.8%) | 334 (37.1%) | <0.001 | 268 (38.6%) | 66 (32.0%) | 0.086 |
| Medicaid | 2,040 (7.9%) | 115 (12.8%) | <0.001 | 95 (13.7%) | 20 (9.7%) | 0.13 |
| BMI | 28.91 (24.82–34.41) | 29.12 (24.26–35.26) | 0.84 | 29.28 (24.43–35.26) | 28.67 (23.91–35.14) | 0.29 |
| HFrEF | 4,052 (22.8%) | 189 (21.0%) | 0.14 | 153 (22.0%) | 36 (17.5%) | 0.16 |
| Hypertension | 18,001 (69.8%) | 665 (73.9%) | 0.008 | 501 (72.2%) | 164 (79.6%) | <0.05 |
| COPD | 8,006 (31.0%) | 263 (29.2%) | 0.25 | 196 (28.2%) | 67 (32.5%) | 0.24 |
| CAD | 8,006 (31.0%) | 269 (29.9%) | 0.47 | 196 (28.2%) | 73 (35.4%) | <0.05 |
| Renal Disease | 7,131 (27.6%) | 317 (35.2%) | <0.001 | 238 (34.3%) | 79 (38.3%) | 0.28 |
| NT-proBNP | 1733 (592–4714) | 2092 (648–6515) | <0.001 | 2276 (704–6598) | 1357 (502–5281) | <0.05 |
| Sodium | 140 (138–141) | 139 (137–142) | 0.016 | 139 (137–142) | 139 (137–142) | 0.49 |
| Chloride | 103 (100–105) | 102 (98–105) | 0.003 | 102 (98–105) | 102 (99–106) | 0.68 |
| Creatinine | 1.1 (.88–1.46) | 1.2 (.88–1.9) | <0.001 | 1.19 (.87–1.88) | 1.3 (.93–1.97) | <0.05 |
| BUN | 22 (16–31) | 26 (17–41.5) | <0.001 | 25 (16–40) | 30 (19–46) | <0.05 |
| HbA1c | 6.2 (5.7–7.3) | 6.3 (5.7–7.5) | 0.08 | 6.3 (5.7–7.5) | 6.5 (5.7–7.7) | 0.6 |
| ACE-I/ARB | 13,354 (51.8%) | 312 (34.7%) | <0.001 | 254 (36.6%) | 58 (28.2%) | <0.05 |
| ARNI | 2,077 (8.0%) | 54 (6.0%) | 0.026 | 48 (6.9%) | 6 (2.9%) | <0.05 |
| Beta Blocker | 13,568 (52.6%) | 429 (47.7%) | 0.004 | 335 (48.3%) | 94 (45.6%) | 0.51 |
| CCB | 6,879 (26.7%) | 283 (31.4%) | 0.001 | 214 (30.8%) | 69 (33.5%) | 0.47 |
| SGLT2i | 810 (3.1%) | 25 (2.8%) | 0.54 | 24 (3.5%) | 1 (0.5%) | 0.02 |
| Warfarin | 2,811 (10.9%) | 81 (9.0%) | 0.07 | 65 (9.4%) | 16 (7.8%) | 0.48 |
| NOAC | 7,052 (27.3%) | 267 (29.7%) | 0.12 | 220 (31.7%) | 47 (22.8%) | 0.01 |
| Diuretic | 15,913 (61.7%) | 518 (57.6%) | 0.013 | 419 (60.4%) | 99 (48.1%) | 0.002 |
| Statin | 16,761 (65.0%) | 556 (61.8%) | 0.05 | 439 (63.3%) | 117 (56.8%) | <0.05 |
Data are presented as median (IQR) for continuous measures, and n (%) for categorical measures.